Neurodegenerative Disorders
Prevail Therapeutics Inc. funds clinical research in Parkinson’s disease and fronto-temporal dementia, with a particular focus on forms linked to GBA1 and progranulin biology.
- Parkinson’s disease
- Parkinson’s disease with GBA1 mutation
- Fronto-temporal dementia with progranulin mutations
The sponsor’s research in this area centers on neurological conditions associated with inherited molecular subtypes and disease-related protein regulation.
Lysosomal Storage Disorders
The company also supports studies in Type 1 Gaucher disease, specifically the peripheral and non-neuronopathic manifestations of the disorder.
- Type 1 Gaucher disease
- Peripheral manifestations
- Non-neuronopathic disease
This area reflects interest in inherited lysosomal conditions with systemic involvement beyond the central nervous system.
Genetic Disease Mechanisms
Across its trial portfolio, Prevail Therapeutics Inc. concentrates on diseases driven by specific genetic alterations, including progranulin mutations and GBA1 mutations.
- Progranulin deficiency
- GBA1-related pathology
- Inherited neurodegeneration
Its clinical research interests align with disorders where molecular defects are closely tied to neurological and lysosomal dysfunction.
Central Nervous System and Biomarker Research
The sponsor’s trials include evaluation of progranulin levels in blood and cerebrospinal fluid, alongside other measures relevant to central nervous system disease biology.
- Blood biomarker assessment
- Cerebrospinal fluid biomarkers
- Central nervous system involvement
These research interests support clinical investigation in neurological diseases where biomarker changes are linked to underlying pathophysiology.
